China Cord Blood Corporation Reports Financial Results for the
Second Quarter and First Half of Fiscal 2013
HONG KONG, Nov. 19, 2012 /PRNewswire-FirstCall/ -- China
Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"),
China's leading provider of cord
blood collection, laboratory testing, hematopoietic stem cell
processing, and stem cell storage services, today announced its
preliminary unaudited financial results for the second quarter and
first half of fiscal year 2013, which ended September 30, 2012.
Second Quarter of Fiscal 2013 Highlights
- Revenues for the second quarter of fiscal 2013 increased by
30.5% to RMB128.5 million
($20.4 million) from RMB98.4 million in the prior year period.
- New subscriber sign-ups and accumulated subscriber base were
18,491 and 274,705, respectively.
- Gross profit increased by 32.3% to RMB101.4 million ($16.1
million) from RMB76.7 million
in the prior year period.
- Gross margin was 78.9%, compared to 77.9% in the prior year
period.
- Operating income increased by 24.7% to RMB47.0 million ($7.5
million) from RMB37.7 million
in the prior year period, after taking into account the increased
management and staff related costs.
- Interest expense amounted to RMB14.1
million ($2.2 million), which
was largely attributable to the convertible note issued to KKR
China Healthcare Investment Limited ("KKR"), compared to
RMB1.2 million in the prior year
period.
- Net income attributable to shareholders increased by 6.2% to
RMB24.7 million ($3.9 million) from RMB23.2
million in the prior year period.
- Operating cash flow for the quarter amounted to RMB142.5 million ($22.7
million).
First Half of Fiscal 2013 Highlights
- Revenues for the first half of fiscal 2013 increased by 31.1%
to RMB243.8 million ($38.8 million) from RMB185.9 million in the prior year period.
- New subscriber sign-up reached 34,951 and accumulated
subscriber base expanded to 274,705.
- Gross profit increased by 33.3% to RMB192.3 million ($30.6
million) from RMB144.3 million
in the prior year period.
- Operating income increased by 33.5% to RMB91.4 million ($14.6
million) from RMB68.5 million
in the prior year period.
- Interest expense amounted to RMB24.3
million ($3.9 million),
compared to RMB1.7 million in the
prior year period.
- Net income attributable to shareholders amounted to
RMB55.8 million ($8.9 million), compared to RMB63.3 million in the prior year period.
- Operating cash flow for the first half of fiscal 2013 was
RMB279.4 million ($44.5 million).
"Coming off of robust growth in our financial performance and
yet another record in new subscriber numbers, we concluded the
first half of fiscal 2013 with notable achievements and records,"
stated Ms. Ting Zheng, Chief Executive Officer of China Cord Blood
Corporation. "A high mark of 18,491 in new subscriber
numbers, which is our highest increase for any single quarter,
reflects our continued commitment to optimize our marketing
strategy to deepen penetration and enhance our subscriber
base. Our management team's execution capabilities have also
been demonstrated by positive performance in such areas as revenue,
operating income and built-up cash flow streams resulting from
greater volume of upfront customer payments. These
achievements have not only established a solid foundation for the
Company to generate long-term sustainable growth, but also provide
a platform for the Company to grasp timely opportunities for
geographical expansion."
Ms. Zheng further commented, "We are very pleased to have
recently received valuable support from KKR and our major
shareholder, Golden Meditech Holdings Limited ("Golden Meditech"),
who share CCBC's vision for growing the Company in China and throughout the Asia-Pacific region. Both KKR and Golden
Meditech bring valuable management resources and strategic
perspectives that fit the Company's expansion plans. Under
the leadership of Mr. Yuen Kam as our newly appointed Chairman and
with his extensive experience in China's healthcare industry, the management
team and I believe that the present synergies will help drive the
Company towards further operational growth and strategic
development."
Summary – The Second Quarter and First Half
Ended September 30,
2011 and 2012
|
Three
Months Ended September 30,
|
|
Six Months
Ended September 30,
|
|
2011
|
|
2012
|
|
2011
|
|
2012
|
(in
thousands)
|
RMB
|
|
RMB
|
US$
|
|
RMB
|
|
RMB
|
US$
|
Revenues
|
98,433
|
|
128,462
|
20,440
|
|
185,891
|
|
243,792
|
38,791
|
Gross
Profit
|
76,676
|
|
101,405
|
16,135
|
|
144,266
|
|
192,346
|
30,605
|
Operating
Income
|
37,725
|
|
47,044
|
7,485
|
|
68,477
|
|
91,442
|
14,550
|
Net Income
Attributable to Shareholders
|
23,249
|
|
24,695
|
3,929
|
|
63,271
|
|
55,788
|
8,878
|
Earnings per Ordinary Shares
- Basic(1) and Diluted (RMB/US$)
|
0.31
|
|
0.34
|
0.05
|
|
0.85
|
|
0.75
|
0.12
|
|
|
|
|
|
|
|
|
|
|
Revenue
Breakdown (%)
|
|
|
|
|
|
|
|
|
|
Processing
Fees
|
74.9%
|
|
76.4%
|
|
|
74.5%
|
|
75.9%
|
|
Storage
Fees
|
25.1%
|
|
23.6%
|
|
|
25.5%
|
|
24.1%
|
|
|
|
|
|
|
|
|
|
|
|
New
Subscribers (persons)
|
13,899
|
|
18,491
|
|
|
26,727
|
|
34,951
|
|
Total
Accumulated Subscribers (persons)
|
212,557
|
|
274,705
|
|
|
212,557
|
|
274,705
|
|
Summary – Selected Cash Flow Statement Items
|
Three
Months Ended
|
|
Six Months
Ended
|
|
September
30, 2012
|
|
September
30, 2012
|
(in
thousands)
|
RMB
|
US$
|
|
RMB
|
US$
|
Net cash
provided by operating activities
|
142,534
|
22,679
|
|
279,406
|
44,457
|
Net cash
used in investing activities
|
(5,896)
|
(938)
|
|
(88,424)
|
(14,069)
|
Net cash
provided by financing activities
|
41,314
|
6,574
|
|
340,360
|
54,156
|
Second Quarter Fiscal 2013 Financial Results
REVENUES. Revenues increased by 30.5% to
RMB128.5 million ($20.4 million) in the second quarter of fiscal
2013 from RMB98.4 million in the
prior year period, driven mainly by a significant increase in new
subscriber sign-ups during the quarter and expansion in our
accumulated subscriber base.
Revenues generated from storage fees increased to RMB30.3 million ($4.8
million), up 22.7% from RMB24.7
million in the prior year period. In light of the
significant increase in new subscribers, revenue from storage fees
accounted for a lesser of 23.6% of total revenues, compared to
25.1% in the prior year period.
Revenues generated from processing fees were RMB98.2 million ($15.6
million), up 33.2% from RMB73.7
million in the prior year period, reflecting 18,491 new
subscriber sign-ups this quarter, a 33.0% annual increase and a
12.3% sequential increase in new subscriber sign-ups.
Revenues generated from processing fees accounted for 76.4%
of total revenues, compared to 74.9% in the prior year period.
GROSS PROFIT. Gross profit for the second
quarter of fiscal 2013 increased by 32.3% to RMB101.4 million ($16.1
million) from RMB76.7 million
in the prior year period, benefiting from economies of scale.
Gross margin was 78.9%, compared to 77.9% in the prior year
period.
OPERATING INCOME. Operating income for the
second quarter increased at a slower pace to RMB47.0 million ($7.5
million) compared to RMB37.7
million in the prior year period. Operating margin was
slightly down to 36.6%, compared to 38.3% in the prior year period,
as a result of an increase in management and staff related costs,
as well as an increase in depreciation expenses as we begin to
depreciate part of the new facility in Guangdong. Depreciation and amortization
expenses for the second quarter were RMB8.3
million ($1.3 million),
compared to RMB7.1 million in the
prior year period.
- Research and Development Expenses. Research
and development expenses remained stable at RMB1.9 million ($0.3
million) compared to RMB1.9
million in the prior year period, a reflection of the
Company's continuous efforts to enhance operations through
technology advancement.
- Sales and Marketing Expenses. Sales and
marketing expenses, increased by 51.0% to RMB23.5 million ($3.7
million) from RMB15.6 million
in the prior year period. These expenses indicated our
continuous reach-out to deeply penetrate into the Beijing market, further marketing campaigns to
outreach to potential subscribers in the Guangdong market, as well as costs for the
building up of development for the Zhejiang market. Sales and marketing
expenses represented 18.3% of revenues in the second quarter of
fiscal 2013, up from 15.8% in the prior year period and 16.7% in
the first quarter of fiscal 2013.
- General and Administrative Expenses.
General and administrative expenses were RMB29.0 million ($4.6
million), compared to RMB21.4
million in the prior year period and RMB25.1 million in the first quarter of fiscal
2013, mainly due to an increase in management and staff related
costs of RMB4.6 million ($0.7 million). As a percentage of revenue,
it increased to 22.6% compared to 21.8% in the prior year period
and compared to 21.7% in the first quarter of fiscal 2013.
OTHER INCOME AND EXPENSES
- Interest Expense. Interest expense
increased to RMB14.1 million
($2.2 million) from RMB1.2 million in the prior year period.
The increase was largely attributable to the issuance of a
convertible note to KKR in April
2012. In the second quarter of fiscal 2013, interest
expense related to the convertible note annual coupon payment
amounted to RMB7.3 million
($1.2 million) and the amortization
of other related costs amounted to RMB6.0
million ($1.0 million).
NET INCOME ATTRIBUTABLE TO SHAREHOLDERS. Net
income attributable to shareholders for the second quarter of
fiscal 2013 increased by 6.2% to RMB24.7
million ($3.9 million) from
RMB23.2 million in the prior year
period. Net margin for the second quarter of fiscal 2013 was
19.2%.
EARNINGS PER SHARE. The terms of the
convertible note issued to KKR provides KKR with the ability to
participate in any Excess Cash Dividend(2). Therefore, the
calculation of basic EPS has taken into consideration KKR's
participating right effect of RMB0.01. Basic and diluted earnings per
ordinary share for the second quarter of fiscal 2013 were
RMB0.34 ($0.05).
LIQUIDITY. As of September 30, 2012, the Company had cash and cash
equivalents of RMB1,324.5 million
($210.7 million) compared to
RMB794.3 million as of March 31, 2012. The Company had total debt
of RMB472.6 million ($75.2 million) as of September 30, 2012. Operating cash flow for
the quarter amounted to RMB142.5
million ($22.7 million).
First Half Fiscal 2013 Financial Results
For the first half of fiscal year 2013, total revenues increased
by 31.1% to RMB243.8 million
($38.8 million) from RMB185.9 million in the prior year period.
The increase was largely attributable to the significant
increase in new subscribers and the expansion of the Company's
accumulated subscriber base to 274,705 subscribers.
Processing fees and storage fees grew by 33.6% and 24.0%,
respectively. Gross profit increased by 33.3% to RMB192.3 million ($30.6
million) from RMB144.3 million
in the prior year period. Operating income increased by 33.5%
to RMB91.4 million ($14.6 million) from RMB68.5 million in the prior year period. Net
income attributable to shareholders amounted to RMB55.8 million ($8.9
million). Basic and diluted earnings per share
attributable to ordinary shares were RMB0.75 ($0.12).
Net cash provided by operating activities in the first half
of fiscal 2013 was RMB279.4 million
($44.5 million).
Ms. Zheng concluded, "Even though we recorded impressive
performance in our operating markets, we are continuing our efforts
to widen market coverage and deepen penetration to capture more of
the large regional market potential presented in Beijing, Guangdong and Zhejiang. We have seen
encouraging market responses during this start-up phase of our
Zhejiang operation while actively
searching for an optimal location to build our facility in the
province. For the Guangdong
market, our new facility is well under way in construction to
increase capacity in this promising region. CCBC recently
completed a transaction with Cordlife Group Limited ("Cordlife"),
which has resulted in the Company now wholly owning our
Guangdong subsidiary, thereby
allowing the Company to fully benefit from the strong sales and
future growth potential of this affluent market. The
strengthening of our long-standing strategic alliance with Cordlife
opens additional avenues for us to develop Pan-Asian markets.
Since April 2012, we have
bought back approximately $20.3
million worth of shares. With the resources and
talents on hand, we aim to enhance shareholder value by expanding
our China and Pan-Asia footprint
while continuing to explore opportunities to reward our
shareholders for their ongoing support."
(1) The
terms of the convertible note issued to KKR provides KKR with the
ability to participate in any excess cash dividend.
Therefore, the calculation of basic EPS has taken into
consideration KKR's participating right effect of RMB0.01 and
RMB0.03 for the three months and six months ended September 30,
2012, respectively.
|
(2)
"Excess Cash Dividend" means any cash dividend to holders of shares
that, together with all other cash dividends previously paid to
holders of shares in the same financial year, exceeds, on a per
share basis, an amount equal to the interest that has accrued and
shall accrue at 7% in such financial year divided by the number of
shares into which the note is convertible at the conversion price
then in effect on the relevant record date.
|
Conference Call
The Company will host a conference call at 8:00 a.m. ET on Tuesday,
November 20, 2012 to discuss its financial performance and
give a brief overview of the Company's recent developments,
followed by a question and answer session. Interested parties
may access the audio webcast through the Company's IR website at
http://ir.chinacordbloodcorp.com. A replay of the webcast
will be accessible two hours after the presentation and available
for three weeks at the same URL link above. Listeners may
also access the call by dialing 1-718-354-1231 or 1-866-519-4004
for US callers or +852-2475-0994 for Hong
Kong callers, access code: 50728737.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with multiple licenses.
Under current PRC government regulations, only one licensed
cord blood banking operator is permitted to operate in each
licensed region and only seven licenses have been authorized as of
today. China Cord Blood Corporation provides cord blood
collection, laboratory testing, hematopoietic stem cell processing
and stem cell storage services. For more information, please
visit our website at http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, and
Section 21E of the Securities Exchange Act of 1934. These
statements relate to future events or the Company's future
financial performance. The Company has attempted to identify
forward-looking statements by terminology including "anticipates",
"believes", "expects", "can", "continue", "could", "estimates",
"intends", "may", "plans", "potential", "predict", "should" or
"will" or the negative of these terms or other comparable
terminology. These statements are only predictions, uncertainties
and other factors may cause the Company's actual results, levels of
activity, performance or achievements to be materially different
from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking
statements. The information in this press release is not intended
to project future performance of the Company. Although the Company
believes that the expectations reflected in the forward-looking
statements are reasonable, the Company does not guarantee future
results, levels of activity, performance or achievements. The
Company expectations are as of the date this press release is
issued, and the Company does not intend to update any of the
forward-looking statements after the date this press release is
issued to confirm these statements to actual results, unless
required by law.
The forward-looking statements included in this press release
are subject to risks, uncertainties and assumptions about the
Company's businesses and business environments. These statements
reflect the Company's current views with respect to future events
and are not a guarantee of future performance. Actual results of
the Company's operations may differ materially from information
contained in the forward-looking statements as a result of risk
factors some of which include, among other things: continued
compliance with government regulations regarding cord blood banking
in the People's Republic of China,
or PRC; changing legislation or regulatory environments in the PRC;
the acceptance by subscribers of the Company's different pricing
and payment options and reaction to the introduction of the
Company's premium-quality pricing strategy; demographic trends in
the regions of the PRC in which the Company is the exclusive
licensed cord blood banking operator; labor and personnel
relations; credit risks affecting the Company's revenue and
profitability; changes in the healthcare industry, including those
which may result in the use of stem cell therapies becoming
redundant or obsolete; the Company's ability to effectively manage
its growth, including implementing effective controls and
procedures and attracting and retaining key management and
personnel; changing interpretations of generally accepted
accounting principles; the availability of capital resources,
including in the form of capital markets financing opportunities,
in light of industry developments affecting issuers that have
pursued a "reverse merger" with an operating company based in
China, as well as general economic
conditions; and other relevant risks detailed in the Company's
filings with the Securities and Exchange Commission.
This announcement contains translations of certain Renminbi
amounts into U.S. dollars at specified rates solely for the
convenience of readers. Unless otherwise noted, all translations
from Renminbi to U.S. dollars as of and for the periods ending
September 30, 2012 were made at the
noon buying rate of RMB6.2848 to
$1.00 on September 28, 2012 in the City of New York for cable transfers in
Renminbi per U.S. dollar as certified for customs purposes by the
Federal Reserve Bank of New York.
China Cord Blood Corporation makes no representation that the
Renminbi or U.S. dollar amounts referred to in this press release
could have been or could be converted into U.S. dollars or
Renminbi, at any particular rate or at all.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
Mr. Rob Koepp
Tel: (+86) 10-6583-7516
U.S. Tel: (646) 405-5185
EXHIBIT
1
CHINA
CORD BLOOD CORPORATION
UNAUDITED CONDENSED CONSOLIDATED BALANCE
SHEETS
As of
March 31 and September 30, 2012
|
|
March
31,
|
|
September
30,
|
|
2012
|
|
2012
|
|
RMB
|
|
RMB
|
|
US$
|
|
(in
thousands except share data)
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
Cash and
cash equivalents
|
794,311
|
|
1,324,507
|
|
210,748
|
Accounts
receivable, less allowance for doubtful accounts
|
|
|
|
|
|
(March 31, 2012: RMB13,916; September 30, 2012:
RMB14,841)
|
79,012
|
|
78,627
|
|
12,511
|
Inventories
|
6,666
|
|
5,074
|
|
807
|
Prepaid
expenses and other receivables
|
11,561
|
|
15,055
|
|
2,395
|
Trading
securities
|
354
|
|
-
|
|
-
|
Deferred
offering costs
|
-
|
|
2,852
|
|
454
|
Deferred
tax assets
|
5,268
|
|
5,715
|
|
909
|
Total
current assets
|
897,172
|
|
1,431,830
|
|
227,824
|
Property,
plant and equipment, net
|
267,862
|
|
345,279
|
|
54,939
|
Non-current prepayments
|
2,863
|
|
3,144
|
|
500
|
Non-current accounts receivable, less allowance for
doubtful accounts
|
|
|
|
|
|
(March 31, 2012: RMB38,628; September 30, 2012:
RMB42,744)
|
254,236
|
|
246,086
|
|
39,156
|
Inventories
|
34,651
|
|
37,773
|
|
6,010
|
Intangible
assets, net
|
129,791
|
|
127,481
|
|
20,284
|
Available-for-sale equity securities
|
98,199
|
|
78,332
|
|
12,464
|
Other
investment
|
134,363
|
|
134,363
|
|
21,379
|
Deferred
offering costs
|
-
|
|
10,183
|
|
1,620
|
Deferred
tax assets
|
5,013
|
|
5,879
|
|
935
|
Total
assets
|
1,824,150
|
|
2,420,350
|
|
385,111
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
Bank
loan
|
45,000
|
|
50,000
|
|
7,956
|
Accounts
payable
|
6,343
|
|
14,234
|
|
2,265
|
Accrued
expenses and other payables
|
33,351
|
|
62,555
|
|
9,953
|
Deferred
revenue
|
106,110
|
|
151,496
|
|
24,105
|
Amounts
due to related party
|
360
|
|
720
|
|
115
|
Income tax
payable
|
5,943
|
|
5,809
|
|
924
|
Total
current liabilities
|
197,107
|
|
284,814
|
|
45,318
|
Convertible notes
|
-
|
|
422,569
|
|
67,237
|
Non-current deferred revenue
|
306,534
|
|
406,359
|
|
64,657
|
Other
non-current liabilities
|
60,420
|
|
81,455
|
|
12,961
|
Deferred
tax liabilities
|
24,462
|
|
23,306
|
|
3,708
|
Total
liabilities
|
588,523
|
|
1,218,503
|
|
193,881
|
|
|
|
|
|
|
EQUITY
|
|
|
|
|
|
Shareholders' equity
|
|
|
|
|
|
Ordinary shares
|
|
|
|
|
|
- US$0.0001 par value, 250,000,000 shares
authorized, 73,140,147
|
|
|
|
|
|
shares
issued and outstanding as of March 31, 2012 and
|
|
|
|
|
|
73,140,147
shares issued and 69,064,092 shares outstanding
|
|
|
|
|
|
as of
September 30, 2012
|
50
|
|
50
|
|
8
|
Additional
paid-in capital
|
865,654
|
|
865,654
|
|
137,737
|
Treasury
stock
|
-
|
|
(72,675)
|
|
(11,564)
|
Accumulated other comprehensive income
|
26,057
|
|
3,705
|
|
589
|
Retained
earnings
|
310,973
|
|
366,761
|
|
58,358
|
Total
shareholders' equity
|
1,202,734
|
|
1,163,495
|
|
185,128
|
Non-controlling interests
|
32,893
|
|
38,352
|
|
6,102
|
Total
equity
|
1,235,627
|
|
1,201,847
|
|
191,230
|
Total
liabilities and equity
|
1,824,150
|
|
2,420,350
|
|
385,111
|
|
|
|
|
|
|
EXHIBIT
2
CHINA
CORD BLOOD CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
COMPREHENSIVE INCOME
For the
Three Months and Six Months ended September 30, 2011 and
2012
|
|
Three
months ended September 30,
|
Six months
ended September 30,
|
|
2011
|
|
2012
|
|
2011
|
|
2012
|
|
RMB
|
|
RMB
|
|
US$
|
|
RMB
|
|
RMB
|
|
US$
|
|
(in
thousands except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
98,433
|
|
128,462
|
|
20,440
|
|
185,891
|
|
243,792
|
|
38,791
|
Direct
costs
|
(21,757)
|
|
(27,057)
|
|
(4,305)
|
|
(41,625)
|
|
(51,446)
|
|
(8,186)
|
Gross
profit
|
76,676
|
|
101,405
|
|
16,135
|
|
144,266
|
|
192,346
|
|
30,605
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
(1,932)
|
|
(1,860)
|
|
(296)
|
|
(3,709)
|
|
(4,123)
|
|
(656)
|
Sales and
marketing
|
(15,575)
|
|
(23,517)
|
|
(3,742)
|
|
(28,181)
|
|
(42,737)
|
|
(6,800)
|
General
and administrative
|
(21,444)
|
|
(28,984)
|
|
(4,612)
|
|
(43,899)
|
|
(54,044)
|
|
(8,599)
|
Total
operating expenses
|
(38,951)
|
|
(54,361)
|
|
(8,650)
|
|
(75,789)
|
|
(100,904)
|
|
(16,055)
|
Operating income
|
37,725
|
|
47,044
|
|
7,485
|
|
68,477
|
|
91,442
|
|
14,550
|
Other
(expense)/income , net
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income
|
3,312
|
|
3,859
|
|
614
|
|
6,451
|
|
7,188
|
|
1,144
|
Interest
expense
|
(1,190)
|
|
(14,089)
|
|
(2,242)
|
|
(1,650)
|
|
(24,265)
|
|
(3,861)
|
Exchange
(loss)/gain
|
(4,956)
|
|
41
|
|
7
|
|
(4,860)
|
|
51
|
|
8
|
Dividend
income
|
-
|
|
-
|
|
-
|
|
7,217
|
|
2,420
|
|
385
|
Others
|
111
|
|
(1,002)
|
|
(160)
|
|
325
|
|
(766)
|
|
(121)
|
Total
other (expense)/income, net
|
(2,723)
|
|
(11,191)
|
|
(1,781)
|
|
7,483
|
|
(15,372)
|
|
(2,445)
|
Income
before income tax
|
35,002
|
|
35,853
|
|
5,704
|
|
75,960
|
|
76,070
|
|
12,105
|
Income tax
expense
|
(9,093)
|
|
(8,466)
|
|
(1,347)
|
|
(7,310)
|
|
(14,801)
|
|
(2,355)
|
Net
income
|
25,909
|
|
27,387
|
|
4,357
|
|
68,650
|
|
61,269
|
|
9,750
|
Income
attributable to non-controlling interests
|
(2,660)
|
|
(2,692)
|
|
(428)
|
|
(5,379)
|
|
(5,481)
|
|
(872)
|
Net
income attributable to shareholders
|
23,249
|
|
24,695
|
|
3,929
|
|
63,271
|
|
55,788
|
|
8,878
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
income per share:
|
|
|
|
|
|
|
|
|
|
|
|
Attributable to ordinary shares
|
|
|
|
|
|
|
|
|
|
|
|
- Basic
|
0.31
|
|
0.34
|
|
0.05
|
|
0.85
|
|
0.75
|
|
0.12
|
- Diluted
|
0.31
|
|
0.34
|
|
0.05
|
|
0.85
|
|
0.75
|
|
0.12
|
Other
comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
- Net effect of foreign currency
translation, net of nil tax
|
122
|
|
(1,007)
|
|
(160)
|
|
(689)
|
|
(2,424)
|
|
(386)
|
- Net unrealized (loss)/gain in
available-for-sale equity securities, net of nil tax
|
(5,976)
|
|
2,624
|
|
418
|
|
(11,508)
|
|
(19,950)
|
|
(3,174)
|
Comprehensive income
|
20,055
|
|
29,004
|
|
4,615
|
|
56,453
|
|
38,895
|
|
6,190
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income attributable to non-controlling
interests
|
(2,680)
|
|
(2,672)
|
|
(425)
|
|
(5,605)
|
|
(5,459)
|
|
(869)
|
Comprehensive income attributable to
shareholders
|
17,375
|
|
26,332
|
|
4,190
|
|
50,848
|
|
33,436
|
|
5,321
|
SOURCE China Cord Blood Corporation